Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Connect MM- The Multiple Myeloma Disease Registry

X
Trial Profile

Connect MM- The Multiple Myeloma Disease Registry

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 12 Dec 2023 Planned End Date changed from 31 Dec 2024 to 15 Aug 2031.
    • 15 Jun 2023 Results analyzing treatment patterns and clinical outcomes in patients with MM previously treated with LEN , presented at the 28th Congress of the European Haematology Association
    • 01 Feb 2023 Results (n=232) assessing the treatment patterns, overall survival, health-related quality of life and healthcare resource use among patients with triple-class refractory multiple myeloma in US clinical practice, published in the Clinical Lymphoma, Myeloma & Leukemia.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top